Bristol-Myers Squibb has entered into a global licensing deal with Oncolys BioPharma, a privately held Japanese biotech, for Festinavir®, a once-daily, orally available nucleoside reverse transcriptase inhibitor (NRTI) in Phase II development for HIV. Oncolys could receive up to US$286 M in upfront and milestone payments as well as tiered royalties on worldwide product sales.